Logo image of CLSN

CELSION CORP (CLSN) Stock Fundamental Analysis

NASDAQ:CLSN - Nasdaq - US15117N6022 - Common Stock - Currency: USD

1.96  0 (0%)

After market: 1.96 0 (0%)

Fundamental Rating

1

Overall CLSN gets a fundamental rating of 1 out of 10. We evaluated CLSN against 572 industry peers in the Biotechnology industry. CLSN may be in some trouble as it scores bad on both profitability and health. CLSN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLSN has reported negative net income.
CLSN Yearly Net Income VS EBIT VS OCF VS FCFCLSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -5M -10M -15M -20M

1.2 Ratios

Industry RankSector Rank
ROA -40.03%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSN Yearly ROA, ROE, ROICCLSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

CLSN does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -5229.82%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSN Yearly Profit, Operating, Gross MarginsCLSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

CLSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLSN has been reduced compared to 1 year ago.
Compared to 1 year ago, CLSN has an improved debt to assets ratio.
CLSN Yearly Shares OutstandingCLSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
CLSN Yearly Total Debt VS Total AssetsCLSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

CLSN has an Altman-Z score of -7.47. This is a bad value and indicates that CLSN is not financially healthy and even has some risk of bankruptcy.
CLSN has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -7.47
ROIC/WACCN/A
WACC10.77%
CLSN Yearly LT Debt VS Equity VS FCFCLSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M

2.3 Liquidity

CLSN has a Current Ratio of 6.52. This indicates that CLSN is financially healthy and has no problem in meeting its short term obligations.
CLSN has a Quick Ratio of 6.52. This indicates that CLSN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 6.52
Quick Ratio 6.52
CLSN Yearly Current Assets VS Current LiabilitesCLSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

CLSN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.02%.
CLSN shows a decrease in Revenue. In the last year, the revenue decreased by -2.91%.
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.33%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y0%
Sales Q2Q%0%

3.2 Future

The Earnings Per Share is expected to grow by 5.59% on average over the next years.
CLSN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -22.71% yearly.
EPS Next Y21.32%
EPS Next 2Y11.03%
EPS Next 3Y14.57%
EPS Next 5Y5.59%
Revenue Next Year0%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CLSN Yearly Revenue VS EstimatesCLSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100K 200K 300K 400K 500K
CLSN Yearly EPS VS EstimatesCLSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSN Price Earnings VS Forward Price EarningsCLSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.03
CLSN Per share dataCLSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as CLSN's earnings are expected to grow with 14.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.03%
EPS Next 3Y14.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELSION CORP

NASDAQ:CLSN (9/20/2022, 8:01:31 PM)

After market: 1.96 0 (0%)

1.96

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2022-08-15/bmo
Earnings (Next)11-14 2022-11-14
Inst Owners0.31%
Inst Owner Change0%
Ins Owners37.95%
Ins Owner Change0%
Market Cap13.91M
Analysts82.5
Price Target27.54 (1305.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.83
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB N/A
EV/EBITDA 1.03
EPS(TTM)-7.21
EYN/A
EPS(NY)-4.23
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.07
BVpS6.63
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -5229.82%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.52
Quick Ratio 6.52
Altman-Z -7.47
F-Score2
WACC10.77%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.33%
EPS Next Y21.32%
EPS Next 2Y11.03%
EPS Next 3Y14.57%
EPS Next 5Y5.59%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y0%
Sales Q2Q%0%
Revenue Next Year0%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.71%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A